Target intelligence / Profile preview

Bcl-2 homologous antagonist-killer (BAK1)

Target
BAK1
Molecular classification
Other, Bcl-2 family protein
01

Overview

Bcl-2 homologous antagonist-killer (BAK1) is a key pro-apoptotic member of the BCL-2 protein family that regulates the intrinsic apoptotic pathway (UniProt Q16611). Located on the outer mitochondrial membrane, BAK1 is activated by BH3-only proteins, prompting it to undergo conformational changes and oligomerize. This oligomerization causes mitochondrial outer membrane permeabilization (MOMP), releasing cytochrome c into the cytosol to initiate caspase-dependent cell death. In oncology, BAK1 expression is frequently downregulated or suppressed by anti-apoptotic proteins, enabling cancer cells to evade apoptosis. Therapeutic agents like BH3 mimetics (e.g., venetoclax, navitoclax) indirectly activate BAK1 by inhibiting its suppressors, such as BCL-2 and BCL-XL, thereby restoring apoptotic signaling in malignancies.

Other names
BAKBCL2L7Bcl-2-like protein 7Apoptosis regulator BAKCDN1
02

Mechanism of action

Indirect activation via inhibition of anti-apoptotic BCL-2 family proteins, or direct activation to induce mitochondrial outer membrane permeabilization (MOMP) and subsequent apoptosis.

03

Biological functions

ApoptosisCell deathSignal transduction
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

ThrombocytopeniaNeutropeniaTumor lysis syndromeOn-target toxicity in healthy tissues
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

BAK protein expressionBAK gene mutation statusMCL-1/BAK ratio

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Bcl-2 homologous antagonist-killer (BAK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bcl-2 homologous antagonist-killer (BAK1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call